In July 2015, an editorial in the "New England Journal of Medicine" cited concerns by Médecins sans Frontières and Oxfam that a spike in drug prices caused by patent extensions could threaten millions of lives. Extending "data exclusivity" provisions would "prevent drug regulatory agencies such as the Food and Drug Administration from registering a generic version of a drug for a certain number of years." The article arugues that TPP could theoretically require corporations be paid compensation for any "lost profits" found to result from a nation's health regulations. The article argues that the provisions in the TPP concerning generic drugs directly target India's pharmaceutical industry. Doctors Without Borders said in November 2015 that it was "extremely concerned about the inclusion of dangerous provisions that would dismantle public health safeguards enshrined in international law and restrict access to price-lowering generic medicines for millions of people." The Australian Public Health Association (PHAA) published a media release in February 2014 that highlighted "the ways in which some of the expected economic gains from the TPPA may be undermined by poor health outcomes, and the economic costs associated with these poor health outcomes."